---
type: "Symbol"
title: "CHENGDA PHARMA (301201.SZ) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/301201.SZ/topics.md"
symbol: "301201.SZ"
parent: "https://longbridge.com/en/quote/301201.SZ.md"
count: 1
datetime: "2026-03-09T16:59:35.817Z"
locales:
  - [en](https://longbridge.com/en/quote/301201.SZ/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301201.SZ/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301201.SZ/topics.md)
---

# CHENGDA PHARMA (301201.SZ) — Community Discussions

### [A 股创科 |301201 诚达药业 IPO，期望涨幅 13%](https://longbridge.com/en/topics/1752310.md)

- Author: [美股大观](https://longbridge.com/en/profiles/3809.md)
- Datetime: 2022-01-09T15:26:17.000Z
- Comments: 0
- 公司主要致力于为跨国制药企业及医药研发机构提供关键医药中间体 CDMO 服务，并从事左旋肉碱系列产品的研发、生产和销售。公司自成立以来坚持深耕医药 CDMO 领域，在药物临床试验和商业化阶段为客户提供关键医药中间体的工艺研发及优化、质量研究和定制生产等服务。经过二十多年的积累，公司所服务的终端药物涉及抗肿瘤、艾滋病、乙肝、丙肝、骨髓纤维化、癫痫、帕金森症等多个治疗领域...

## References

- [CHENGDA PHARMA (301201.SZ)](https://longbridge.com/en/quote/301201.SZ.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/301201.SZ/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/301201.SZ/topics.md)